<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786759</url>
  </required_header>
  <id_info>
    <org_study_id>HFBA</org_study_id>
    <nct_id>NCT01786759</nct_id>
  </id_info>
  <brief_title>Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion</brief_title>
  <official_title>Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiology of parenteral nutrition-associated cholestasis(PNAC)although elusive is thought&#xD;
      to be multifactorial, and proposed theories also include problems arising from lipid&#xD;
      emulsions, leading us to explore alternative products available elsewhere.So we compare the&#xD;
      different fat emulsion, and want to see if the olive oil lipid emulsions can improve hepatic&#xD;
      tolerance in preterm infant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parenteral nutrition (PN) has been widely and successfully used in the pediatric population&#xD;
      for more than 40 years, the most serious and significant life-threatening complication today&#xD;
      continues to be parenteral nutrition-associated cholestasis(PNAC). Parenteral&#xD;
      nutrition-associated cholestasis is indeed the most worrisome complication because it is&#xD;
      difficult to treat and may progress to eventual cirrhosis and liver failure namely parenteral&#xD;
      nutrition-associated liver disease (PNALD).&#xD;
&#xD;
      Two types of lipid emulsions are currently used for adult as well as pediatric patients: one&#xD;
      lipid emulsions prepared from soybean oil that are composed of long-chain triacylglycerols&#xD;
      (LCTs), and the other lipid emulsions composed of 50% medium-chain triacylglycerols (MCTs)&#xD;
      and 50% LCT soybean oil. A new lipid emulsion prepared from a mixture of soybean oil and&#xD;
      olive oil contains only LCTs and has a lower proportion (20%) of polyunsaturated fatty&#xD;
      acids(PUFAs)and 60% monounsaturated fatty acids (MUFAs). So we compare the different fat&#xD;
      emulsion, and want to see if the olive oil lipid emulsions can improve hepatic tolerance in&#xD;
      preterm infant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver function</measure>
    <time_frame>Change from Baseline in fatty acid at 7 days and 14 days</time_frame>
    <description>Total Bile Acid(TBA),alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(AKP),Î³-glutamyl transpeptidase(GGT),total bilirubin(Tbi),Direct bilirubin(Dbi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bile acid</measure>
    <time_frame>Change from Baseline in fatty acid at 7 days and 14 days</time_frame>
    <description>cholic acid,deoxycholic acid,Chenodeoxycholic Acid,ursodeoxycholic acid,lithocholic acid,et al.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preterm Infants</condition>
  <arm_group>
    <arm_group_label>LCT lipid emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the LCT lipid emulsion is Intralipid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive oil lipid emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the olive oil lipid emulsion is ClinOleic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ClinOleic</intervention_name>
    <description>the lipid of all-in-one, 0.5-3.5g/kg.d</description>
    <arm_group_label>LCT lipid emulsion</arm_group_label>
    <arm_group_label>Olive oil lipid emulsion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>the lipid of all-in-one, 0.5-3.5g/kg.d</description>
    <arm_group_label>LCT lipid emulsion</arm_group_label>
    <arm_group_label>Olive oil lipid emulsion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants of both genders&#xD;
&#xD;
          -  Hospitalized&#xD;
&#xD;
          -  The parent of the infant agreed to participate by signing an informed consent form&#xD;
&#xD;
          -  Infants admitted hospital within 72 hours after birth(gestational age&lt;37 weeks)&#xD;
&#xD;
          -  Birth weight &lt;= 2000g&#xD;
&#xD;
          -  No PN support contraindications&#xD;
&#xD;
          -  Parenteral nutrition for 14 days or more&#xD;
&#xD;
          -  The parent of the infant is to sign an informed consent form prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving PN before screening&#xD;
&#xD;
          -  Enteral nutrition(EN)caloric&gt;10%&#xD;
&#xD;
          -  Obstruction jaundice&#xD;
&#xD;
          -  Suspected or identified biliary tract atresia&#xD;
&#xD;
          -  Neonatal hepatitis&#xD;
&#xD;
          -  Infants with liver markers &gt;2 times normal levels&#xD;
&#xD;
          -  Infants with renal markers &gt;2 times normal levels&#xD;
&#xD;
          -  Congenital metabolic situations&#xD;
&#xD;
          -  Identified as having major chromosomal disease&#xD;
&#xD;
          -  Cytomegaoviyns(CMV), virus hepatitis and syphilis infection&#xD;
&#xD;
          -  Congenital or acquired immune deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Cai, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Xin Hua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Wang, PhD</last_name>
    <phone>8613611884226</phone>
    <email>wangying_ssmu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yexuan Tao, PhD</last_name>
      <phone>13818334664</phone>
      <email>taoyexuan@hotmail.cm</email>
    </contact>
    <investigator>
      <last_name>Wei Cai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kejun Zhou, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingya Tang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lina Lu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Wei Cai</investigator_full_name>
    <investigator_title>vice-president</investigator_title>
  </responsible_party>
  <keyword>lipids</keyword>
  <keyword>preterm infants</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>liver function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

